BidaskClub upgraded shares of Novavax, Inc. (NASDAQ:NVAX) from a sell rating to a hold rating in a research note released on Thursday.

Several other research firms have also weighed in on NVAX. Zacks Investment Research lowered shares of Novavax from a buy rating to a hold rating in a research note on Friday, June 9th. Piper Jaffray Companies reiterated a hold rating and set a $1.50 price objective on shares of Novavax in a research note on Wednesday, July 26th. Chardan Capital reiterated a neutral rating and set a $1.50 price objective on shares of Novavax in a research note on Thursday. ValuEngine lowered shares of Novavax from a sell rating to a strong sell rating in a research note on Friday, June 2nd. Finally, Cantor Fitzgerald reiterated a hold rating and set a $2.00 price objective on shares of Novavax in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $5.61.

Shares of Novavax (NVAX) traded up 6.7007% during trading on Thursday, reaching $1.0239. The company had a trading volume of 5,881,067 shares. The stock’s market capitalization is $289.35 million. The stock has a 50 day moving average of $1.17 and a 200 day moving average of $1.18. Novavax has a 52-week low of $0.73 and a 52-week high of $8.49.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The business had revenue of $5.68 million for the quarter, compared to analysts’ expectations of $6.17 million. The company’s quarterly revenue was up 34.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.29) earnings per share. Equities research analysts forecast that Novavax will post ($0.61) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/novavax-inc-nvax-upgraded-at-bidaskclub/1464205.html.

In other news, insider Stanley C. Erck purchased 50,000 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were bought at an average price of $0.84 per share, for a total transaction of $42,000.00. Following the completion of the purchase, the insider now owns 128,279 shares of the company’s stock, valued at $107,754.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 105,000 shares of company stock worth $90,800 in the last 90 days. 4.00% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the stock. HighTower Advisors LLC raised its stake in shares of Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 5,250 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Novavax by 2.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 203,996 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 5,704 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Novavax by 2.7% in the first quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock valued at $440,000 after buying an additional 8,966 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Novavax by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock valued at $1,555,000 after buying an additional 10,347 shares during the last quarter. Finally, American International Group Inc. raised its stake in shares of Novavax by 7.1% in the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,965 shares during the last quarter. Institutional investors own 50.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.